GlaxoSmithKline seeks US approval for shingles vaccine Shingrix
The company submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) to market the vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or more.
